TriangleNab paclitaxel (NCT05825066)
Nab paclitaxel trial for Pancreas Adenocarcinoma (NCT05825066). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with borderline-removable or locally advanced pancreatic adenocarcinoma. Prior gemcitabine, nab-paclitaxel or FOLFIRINOX for pancreatic cancer excludes participation.
The idea: start with a month of gemcitabine plus nab-paclitaxel infusions, then a month of modified FOLFIRINOX. Gemcitabine disrupts DNA production; nab-paclitaxel blocks cell division. Researchers assess whether sequential chemotherapy permits surgery with clear margins. Scans check progress every eight weeks. After four months, the care team chooses surgery, radiation or chemotherapy; surgery is not assured.
This phase 2 study plans 64 patients. Ravi Paluri leads two recruiting North Carolina sites.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.